The estimated Net Worth of Michael R Bristow is at least $660 mil dollars as of 4 April 2017. Michael Bristow owns over 720 units of ARCA biopharma Inc stock worth over $98,772 and over the last 15 years he sold ABIO stock worth over $59,384. In addition, he makes $501,400 as President, Chief Executive Officer y Director at ARCA biopharma Inc.
Michael has made over 10 trades of the ARCA biopharma Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 720 units of ABIO stock worth $1,735 on 4 April 2017.
The largest trade he's ever made was buying 1,069,290 units of ARCA biopharma Inc stock on 25 January 2013 worth over $502,566. On average, Michael trades about 45,714 units every 64 days since 2009. As of 4 April 2017 he still owns at least 41,155 units of ARCA biopharma Inc stock.
You can see the complete history of Michael Bristow stock trades at the bottom of the page.
Dr. Michael R. Bristow Ph.D., M.D is President, Chief Executive Officer, Director of ARCA biopharma Inc. Prior to that time, Dr. Bristow served as the Company’s Chief Science and Medical Officer and a director since the merger with Nuvelo. Dr. Bristow has also served as a director of ARCA Colorado since November 2006. Dr. Bristow was one of the founders of ARCA Colorado in September 2004, and served as its Chairman and Chief Executive Officer from that date until he was appointed to the position of Chief Science and Medical Officer in November 2006. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc. and served as Myogen’s Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. Dr. Bristow also has experience with and knowledge of ARCA’s business, as the founder and former Chief Science and Medical Officer of ARCA Colorado, and the current President and Chief Executive Officer of the Company, and as a Board member of ARCA Colorado since 2005, and of the Company since January 2009.
As the President, Chief Executive Officer y Director of ARCA biopharma Inc, the total compensation of Michael Bristow at ARCA biopharma Inc is $501,400. There are no executives at ARCA biopharma Inc getting paid more.
Michael Bristow is 71, he's been the President, Chief Executive Officer y Director of ARCA biopharma Inc since 2009. There are 2 older and 10 younger executives at ARCA biopharma Inc. The oldest executive at ARCA biopharma Inc is Dr. Michael R. Bristow M.D., Ph.D., 76, who is the Co-Founder, Pres, CEO & Director.
Michael's mailing address filed with the SEC is 10170 CHURCH RANCH WAY, SUITE 100, WESTMINSTER, CO, 80021.
Over the last 16 years, insiders at ARCA biopharma Inc have traded over $9,048,465 worth of ARCA biopharma Inc stock and bought 3,605,825 units worth $6,507,167 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of $636,994. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth $17,047.
arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.
ARCA biopharma Inc executives and other stock owners filed with the SEC include: